{u'keywords': [u'Therapeutic Goods Act', u'New South Wales', u'Pan', u'Markethaven', u'Mr', u'proceeding', u'expert advisory group', u'Commonwealth', u'Wales District Registry', u'South Wales District', u'Mr Selim', u'TGA', u'representative proceeding', u'Markethaven Sponsor Notice', u'Selim proceeding', u'Vita Health proceeding', u'personal respondents', u'proceedings', u'Federal Court', u'Australian Naturalcare proceeding', u'Mr Dugan', u'Australian Capital Territory', u'Mr Sheahan', u'Mr Dallen', u'Ms Maclachlan', u'imminent risk', u'Pan Pharmaceuticals', u'recall notice', u'Mr Sid Sarantis', u'products', u'suspension notice', u'Markethaven proceeding', u'application', u'Pan products', u'company arrangement', u'Mr Cesarin', u'representative proceeding states', u'Therapeutic Goods Administration', u'Mr Fraser', u'representative proceeding potential', u'pan strategy', u'Mr Lock', u'Federal Court Rules', u'Sheahan Lock Partners', u'voluntary product recall', u'Pan product range', u'Mr Slater', u'Australia Act', u'Mr Tribe', u'McLachlan Thorpe Partners'], u'casename': u'Markethaven Pty Ltd (subject to Deed of Company Arrangement) v Commonwealth of Australia [2009] FCA 694 (29 June 2009)', u'filename': u'training_data/09_694.xml'}